Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $2.08 Analyst target: $5.74 Upside: 175.96%
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.